Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H29FN2O2 |
| Molecular Weight | 348.4549 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1CCN(CCCN2C(=O)COC3=CC(F)=CC=C23)CC1
InChI
InChIKey=BWAKMLKESHKOHK-UHFFFAOYSA-N
InChI=1S/C20H29FN2O2/c1-2-3-5-16-8-12-22(13-9-16)10-4-11-23-18-7-6-17(21)14-19(18)25-15-20(23)24/h6-7,14,16H,2-5,8-13,15H2,1H3
| Molecular Formula | C20H29FN2O2 |
| Molecular Weight | 348.4549 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one) is a selective muscarinic M1 receptor agonist. The muscarinic M1 receptor agonist property of AC260584 contributes to its enhancement of cortical acetylcholine and dopamine efflux. In animal studies AC-260584 has a behavioral profile consistent with antipsychotic-like efficacy with the potential to improve cognitive performance and shows reduced liability for extrapyramidal symptoms.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. | 2010-02 |
|
| Confocal Analysis of Cholinergic and Dopaminergic Inputs onto Pyramidal Cells in the Prefrontal Cortex of Rodents. | 2010 |
|
| Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. | 2009-09 |
|
| Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. | 2008-10-31 |
|
| Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. | 2008-06 |
|
| AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. | 2007-10-31 |
|
| Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. | 2006-12 |
Sample Use Guides
Using microdialysis in awake, freely moving rats, AC260584, 3 and 10, but not 1 mg/kg (s.c.), significantly increased dopamine release in the medial prefrontal cortex and hippocampus. However, only the high dose of AC260584, 10 mg/kg (s.c.), significantly increased acetylcholine release in these regions.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:54:48 GMT 2025
by
admin
on
Mon Mar 31 21:54:48 GMT 2025
|
| Record UNII |
M4PN46N313
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9928284
Created by
admin on Mon Mar 31 21:54:48 GMT 2025 , Edited by admin on Mon Mar 31 21:54:48 GMT 2025
|
PRIMARY | |||
|
M4PN46N313
Created by
admin on Mon Mar 31 21:54:48 GMT 2025 , Edited by admin on Mon Mar 31 21:54:48 GMT 2025
|
PRIMARY | |||
|
560083-42-3
Created by
admin on Mon Mar 31 21:54:48 GMT 2025 , Edited by admin on Mon Mar 31 21:54:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
